Global Innovative Platforms Announces Completion of First Phase of Breath Test Study for Early Heartworm Detection
MWN-AI** Summary
Global Innovative Platforms Inc. (OTC: GIPL) has successfully completed the first phase of its study on a breath-based diagnostic method aimed at the early detection of heartworm disease in dogs. Announced on October 7, 2025, the study included over 100 breath samples and was designed to validate data that could lead to a non-invasive, point-of-care test for detecting heartworm infections sooner than current diagnostic methods, which typically identify infections only after a six-month period.
CEO Andrew Brown emphasized the importance of early detection, stating, "Our goal is to create a simple and non-invasive breath test that veterinary teams can use to potentially identify infections earlier." The need for such advancement is underscored by the American Heartworm Society's recommendation for dogs to be tested starting at six months of age and then annually thereafter.
Dr. Lindsay Starkey, leading the research team, noted that the initial findings are promising and that further exploration into breath analysis could enhance diagnostic capabilities. The study spanned twelve months and was supervised by parasitologist Dr. Elyssa Campbell, who highlighted the team's commitment and the potential of breath analysis as a breakthrough in veterinary diagnostics.
As Global Innovative Platforms moves forward, it plans to continue its research to identify heartworm breath markers and potentially develop a proprietary diagnostic device that could detect multiple conditions via a single breath analysis. The company is dedicated to advancing animal health through non-invasive technologies that not only detect diseases but also monitor treatment effectiveness and evaluate environmental health risks.
This innovative approach represents a significant step towards improving the care of pets while enhancing the efficacy of heartworm diagnostics in veterinary practices.
MWN-AI** Analysis
Global Innovative Platforms Inc. (OTC: GIPL) has recently announced the completion of the first phase of a significant study focused on the development of a breath-based diagnostic test for early heartworm detection in dogs. This milestone indicates GIPL's potential to introduce innovative technologies to the veterinary market, which could drastically improve early detection and intervention strategies for heartworm disease.
The implications of this development could be substantial, as current diagnostic methods require a six-month waiting period before reliable detection can occur. By shortening this timeline, GIPL positions itself in a niche market that seeks to enhance animal health outcomes. The success of such a product not only serves the canine population but also addresses a broader industry need for improved veterinary diagnostics.
From an investment perspective, GIPL could represent an attractive opportunity moving forward. Initial findings from this first phase are positive, which may lead to increased investor confidence and potential for capital infusions to aid in further research and product development. However, investors should remain cautious and closely monitor forthcoming phases, as the announcement included forward-looking statements laden with potential risks, including uncertainties surrounding research outcomes and regulatory processes.
Additionally, the veterinary diagnostic market is growing, driven by increasing pet ownership and rising awareness of animal health. A successful breath test could differentiate GIPL from competitors, providing it with a unique selling proposition that could capture market share.
Investors should consider establishing a position in GIPL, particularly as they advance toward subsequent research phases. However, remaining vigilant on their progress and regulatory developments will be essential in assessing the viability of this promising opportunity in the canine healthcare market.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
MAITLAND, Fla., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Global Innovative Platforms Inc. (OTC: GIPL) today announced completion of the first phase of its research into breath-based diagnostics for detecting heartworm disease in dogs. The initial study included over 100 samples and focused on validating data to support development of a point-of-care, non-invasive test designed to detect infection earlier than the current industry standard of six months.
“Early detection is the key to protecting dogs from the serious effects of heartworm,” said Andrew Brown, CEO of Global Innovative Platforms. “Our goal is to create a simple and non-invasive breath test that veterinary teams can use to potentially identify infections earlier than available heartworm diagnostic tests. If successful, earlier detection could enable veterinarians and owners the opportunity to intervene sooner, potentially helping dogs live healthier, longer lives.”
The American Heartworm Society currently recommends testing dogs beginning at six months of age and annually thereafter. At present, there is no point-of-care diagnostic widely available that can reliably identify heartworm infection until the infection has been present for approximately six months or more in that dog.
Dr. Lindsay Starkey, DVM, PhD, DACVM, who is leading the research team at Global Innovative, commented: “I am always looking for new ways to improve animal health. Working on this project is exciting, and the initial data is encouraging. We look forward to continuing the research and exploring how breath analysis may contribute to earlier, more effective detection. Dr. Starkey worked alongside Drs. Byron Blagburn and Sarah Zohdy, both of whom were pioneers in the initial heartworm breath research starting in 2017.
Additional on-site testing was overseen by parasitologist Dr. Elyssa Campbell, PhD. The twelve-month study period involved collecting and analyzing over 100 breath samples under her supervision. Dr. Campbell commented “I’m grateful to be working with such a talented team and committed to continuing this work. The data we have gathered show a lot of promise and reinforces our belief that breath analysis could be a significant step forward in veterinary diagnostics.”
Global Innovative is planning further research seeking to confirm heartworm breath markers and expand testing. If successful, the company may pursue development of a proprietary diagnostic device with the goal of allowing for it to have the potential to detect multiple conditions through a single breath analysis.
About Global Innovative Platforms Inc.
Global Innovative Platforms Inc. (OTC: GIPL) is focused on advancing animal health through non-invasive breath analysis and air quality technology. The Company’s Animal Health Division is developing diagnostic tools designed to detect disease, monitor treatment effectiveness, and assess environmental and food-related health risks.
Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. These statements involve risks and uncertainties that could cause actual results to differ materially, including but not limited to risks related to research and development outcomes, regulatory approvals, market acceptance, and other factors described in Global Innovative’s filings with the SEC. See the Company’s Annual Report Form 10-K for filed at www.sec.gov for other risk factors which investors should consider. These forward-looking statements speak only as to the date of this announcement and cannot be relied upon as a guide to future performance. Global Innovative expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained in this announcement to reflect any changes in its expectations with regard thereto or any change in events, conditions or circumstances on which any statement is based.
Media Contact:
Andrew Brown, CEO
Andrew@GIPLinc.com
321.230.3739
FAQ**
What are the next steps for Global Innovative Platforms Inc GIPL in further developing their breath-based diagnostic test for heartworm disease following this initial research phase?
How does Global Innovative Platforms Inc GIPL plan to address the potential regulatory hurdles associated with bringing their breath diagnostic tests to market?
Can Global Innovative Platforms Inc GIPL provide insights on the timeline for commercializing their non-invasive breath test for heartworm disease after validating further research findings?
What strategies does Global Innovative Platforms Inc GIPL intend to implement to facilitate market acceptance of their innovative breath analysis technology in the veterinary community?
**MWN-AI FAQ is based on asking OpenAI questions about Global Innovative Platforms Inc (OTC: GIPL).
NASDAQ: GIPL
GIPL Trading
169900.0% G/L:
$0.51 Last:
440 Volume:
$0.51 Open:
